Overview
LEGN market data
Price History
LEGN price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.81 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.38 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $16.24 – $45.30 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $4.4K · P/B 3.97 · P/S 3.84.
Company news
UBS Downgrades Legend Biotech to Neutral, Lowers Price Target to $28Benzinga · Jul 24, 2026, 11:27 AM
Top 3 Health Care Stocks That May Rocket Higher In JulyBenzinga · Jul 20, 2026, 10:03 AM
JP Morgan Reinstates Neutral on Legend Biotech, Announces $35 Price TargetBenzinga · Jul 13, 2026, 11:01 AM
RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $63Benzinga · Jul 7, 2026, 4:25 PM
Why Is Legend Biotech Stock Falling Thursday?Benzinga · Jun 18, 2026, 1:15 PM
Legend Biotech, Sleep Number And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionBenzinga · Jun 18, 2026, 12:05 PM
Legend Biotech Commences $225M Offering Of Its American Depositary SharesBenzinga · Jun 17, 2026, 8:35 PM
UBS Maintains Buy on Legend Biotech, Raises Price Target to $49Benzinga · Jun 3, 2026, 6:45 PM
Legend Biotech shares are trading higher after the company reported preliminary clinical data for LB2501Benzinga · Jun 2, 2026, 2:32 PM
Legend Biotech Reports 100% Response Rate And 83% Complete Remission Rate In Phase 1 Trial Of LB2501 In Vivo Dual-Targeting CAR-T Therapy For Relapsed/Refractory B-Cell LymphomaBenzinga · Jun 2, 2026, 1:33 PM